Skip to content
Subscriber Only

Novavax Rallies After Vaccine Results Deliver a Wild Ride

  • Stock jumps to nearly five-year high after early Covid-19 data
  • JPMorgan upgrades rating saying results look ‘best in class’
Bloomberg business news
Novavax Aims to Deploy Covid-19 Vaccine by December: R&D Head
Updated on

Novavax Inc. shares touched a five-year high as investors assessed early data on its experimental vaccine for Covid-19.

The stock surged as much as 21%, after sinking in extended trading Tuesday. Novavax has rallied more than 4,300% so far this year on speculation about the potential for its vaccine.